BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 19188679)

  • 1. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.
    Zhu ZH; Sun BY; Ma Y; Shao JY; Long H; Zhang X; Fu JH; Zhang LJ; Su XD; Wu QL; Ling P; Chen M; Xie ZM; Hu Y; Rong TH
    J Clin Oncol; 2009 Mar; 27(7):1091-9. PubMed ID: 19188679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
    Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
    Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances].
    Zhu ZH; Rong TH; Zeng CG; Wu QL; Ma Y; Huang XP; Li BJ; Zhang PY; Zhao JM; Hu W; Zhang SY; Yu H; Ma GW; Zhang LJ; Wen ZS; Fu JH; Long H
    Ai Zheng; 2005 Jul; 24(7):865-9. PubMed ID: 16004817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.
    Lu C; Soria JC; Tang X; Xu XC; Wang L; Mao L; Lotan R; Kemp B; Bekele BN; Feng L; Hong WK; Khuri FR
    J Clin Oncol; 2004 Nov; 22(22):4575-83. PubMed ID: 15542809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
    Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N
    Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A five-gene signature and clinical outcome in non-small-cell lung cancer.
    Chen HY; Yu SL; Chen CH; Chang GC; Chen CY; Yuan A; Cheng CL; Wang CH; Terng HJ; Kao SF; Chan WK; Li HN; Liu CC; Singh S; Chen WJ; Chen JJ; Yang PC
    N Engl J Med; 2007 Jan; 356(1):11-20. PubMed ID: 17202451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
    Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
    Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
    Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
    Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
    Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
    Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
    J Clin Oncol; 2004 Aug; 22(16):3230-7. PubMed ID: 15310766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
    Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
    Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
    Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
    J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
    Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
    Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer.
    Aljada IS; Ramnath N; Donohue K; Harvey S; Brooks JJ; Wiseman SM; Khoury T; Loewen G; Slocum HK; Anderson TM; Bepler G; Tan D
    J Clin Oncol; 2004 Aug; 22(16):3218-29. PubMed ID: 15249585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
    Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
    Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
    Li L; Mei TH; Zhou XD; Zhang XG
    Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.